Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Merck
QuintilesIMS
Cantor Fitzgerald
Cerilliant
Farmers Insurance
UBS
Johnson and Johnson
Colorcon

Generated: November 12, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 019901

« Back to Dashboard

NDA 019901 describes ALTACE, which is a drug marketed by King Pharms Llc and King Pfizer and is included in two NDAs. It is available from one supplier. There is one patent protecting this drug. Additional details are available on the ALTACE profile page.

The generic ingredient in ALTACE is ramipril. There are nineteen drug master file entries for this compound. Thirty-four suppliers are listed for this compound. Additional details are available on the ramipril profile page.
Summary for 019901
Tradename:ALTACE
Applicant:King Pharms Llc
Ingredient:ramipril
Patents:1
Formulation / Manufacturing:see details
Pharmacology for NDA: 019901
Medical Subject Heading (MeSH) Categories for 019901
Suppliers and Packaging for NDA: 019901
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ALTACE ramipril CAPSULE;ORAL 019901 NDA Pfizer Laboratories Div Pfizer Inc 61570-110 61570-110-01 100 CAPSULE in 1 BOTTLE (61570-110-01)
ALTACE ramipril CAPSULE;ORAL 019901 NDA Pfizer Laboratories Div Pfizer Inc 61570-111 61570-111-01 100 CAPSULE in 1 BOTTLE (61570-111-01)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrength1.25MG
Approval Date:Jan 28, 1991TE:ABRLD:Yes
Patent:➤ Sign UpPatent Expiration:Aug 30, 2020Product Flag?Substance Flag?Delist Request?
Patented Use:METHOD OF REDUCING RISK OF MYOCARDIAL INFARCTION, STROKE AND DEATH

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrength2.5MG
Approval Date:Jan 28, 1991TE:ABRLD:Yes
Patent:➤ Sign UpPatent Expiration:Aug 30, 2020Product Flag?Substance Flag?Delist Request?
Patented Use:METHOD OF REDUCING RISK OF MYOCARDIAL INFARCTION, STROKE AND DEATH

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrength5MG
Approval Date:Jan 28, 1991TE:ABRLD:Yes
Patent:➤ Sign UpPatent Expiration:Aug 30, 2020Product Flag?Substance Flag?Delist Request?
Patented Use:METHOD OF REDUCING RISK OF MYOCARDIAL INFARCTION, STROKE AND DEATH

Expired US Patents for NDA 019901

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
King Pharms Llc ALTACE ramipril CAPSULE;ORAL 019901-003 Jan 28, 1991 ➤ Sign Up ➤ Sign Up
King Pharms Llc ALTACE ramipril CAPSULE;ORAL 019901-001 Jan 28, 1991 ➤ Sign Up ➤ Sign Up
King Pharms Llc ALTACE ramipril CAPSULE;ORAL 019901-002 Jan 28, 1991 ➤ Sign Up ➤ Sign Up
King Pharms Llc ALTACE ramipril CAPSULE;ORAL 019901-004 Jan 28, 1991 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Cipla
McKinsey
Federal Trade Commission
Daiichi Sankyo
Cerilliant
Accenture
Fish and Richardson
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.